B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MME

MOLECULAR TARGET

membrane metalloendopeptidase

UniProt: P08473NCBI Gene: 43115 compounds

MME (membrane metalloendopeptidase) is targeted by 5 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MME

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Thiorphan3.3327
2actinonin3.1823
3phosphoramidon3.1422
4omapatrilat2.309
5kelatorphan1.956

About MME as a Drug Target

MME (membrane metalloendopeptidase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 5 compounds with documented MME interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MME inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.